← Leaderboards
Roham Zamanian
Stanford University
$6,654,663
Attributed
$9,492,240
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,492,240 · 3
By mechanism
P01$3,817,085 · 1
R01$3,677,031 · 1
UG3$1,998,124 · 1
Top collaborators
- Steven M Kawut5 shared
- Marlene Rabinovitch1 shared
Most similar at Stanford University
Same institution · by research overlap
- Marlene Rabinovitch$40,032,014
- Kalanit Grill-Spector$13,661,659
- Maarten G Lansberg$12,308,726
- Michael B Manookin$4,866,703
- Scott Dexter Boyd$18,651,021
Others in their field
Other Emerging Leaders on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$49,374,001
- Prasant Mohapatra · University Of California At Davis$40,346,250
- Greg Yothers · University Of Chicago$35,003,821
Research focus
LungPharmaceutical PreparationsChronicEndothelial CellsPulmonary Arterial HypertensionBiologicalAdultProteomicsPulmonary HypertensionPersonalized MedicineGrantPreclinical StudyBaseInflammatoryInflammationLeukocyte ElastaseHemodynamicsBlood VesselsHeritabilityElastasesFollow-UpDoseBone Morphogenetic Protein ReceptorsDrug Kinetics
Grant awards (11)
1/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)$1,998,124
UG3 · FY2025 · HL · contact PI
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$714,004
R01 · FY2025 · HL
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$683,215
R01 · FY2024 · HL
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$692,797
R01 · FY2023 · HL
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$735,810
R01 · FY2022 · HL
Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension$851,205
R01 · FY2021 · HL
Clinical Development of Elafin as a PAH Therapy$723,280
P01 · FY2021 · HL · contact PI
Clinical Development of Elafin as a PAH Therapy$723,280
P01 · FY2020 · HL · contact PI
Clinical Development of Elafin as a PAH Therapy$721,906
P01 · FY2019 · HL · contact PI
Clinical Development of Elafin as a PAH Therapy$864,097
P01 · FY2018 · HL · contact PI
Clinical Development of Elafin as a PAH Therapy$784,522
P01 · FY2017 · HL · contact PI